Physician profile
Mark S Sugar
NPI 1013959253
$2,727.45
in general payments reported to CMS, 2019-2025
23 companies · $854 in 2025
The $854 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $54.36 · 2022: $280 · 2023: $754 · 2024: $614 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $412.80 | 2019-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $344.15 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $318.00 | 2022-2025 | Hyqvia, Cuvitru, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $293.90 | 2020-2025 | Dupixent |
| Pfizer INC. | $213.28 | 2019-2024 | |
| Abbvie INC. | $187.79 | 2022-2025 | Rinvoq |
| Astrazeneca Pharmaceuticals Lp | $160.50 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Csl Behring | $128.99 | 2020-2025 | Hizentra |
| Incyte Corporation | $102.51 | 2022-2023 | Opzelura |
| Novartis Pharmaceuticals Corporation | $97.09 | 2019-2025 | |
| Optinose US, INC. | $72.33 | 2019-2025 | |
| Azurity Pharmaceuticals, INC. | $67.75 | 2025 | Alvesco |
| Blueprint Medicines Corporation | $51.81 | 2023 | Ayvakit |
| Pharming Healthcare, INC. | $43.65 | 2024 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $42.12 | 2025 | Neffy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.02 | 2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.18 | 2022 | |
| Kaleo, INC. | $24.71 | 2024 | Auvi-Q |
| Hikma Pharmaceuticals USA | $22.84 | 2023 | Ryaltris |
| Galderma Laboratories, L.P. | $21.28 | 2025 | Nemluvio |
| Horizon Therapeutics Plc | $20.60 | 2019 | |
| Gc Biopharma USA, INC. | $20.07 | 2024 | Alyglo |
| Shire North American Group INC | $18.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sugar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.